查看购物车
  • Traditional Chinese
  • English
封面
市场调查报告书
商品编码
1407386

製药市场中的生成人工智慧 - 2018-2028 年全球产业规模、份额、趋势、机会和预测，按药物类型、按应用、技术区域和竞争细分

Generative AI in Pharmaceutical Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, 2018-2028 Segmented By Drug Type, By Application, By Technology Region and Competition
出版日期: | 出版商: TechSci Research | 英文 190 Pages | 商品交期: 2-3个工作天内

价格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

简介目录

2022 年，全球製药市场生成式人工智慧 (Generative AI) 价值达 19.6 亿美元，预计在预测期内将强劲成长，到 2028 年复合CAGR为27.62%。全球製药市场生成式人工智慧(Generative AI ) 正在见证人工智慧带来的变革浪潮 ( AI）继续革新製药产业。生成式人工智慧是人工智慧的一个子集，它利用先进的演算法和模型来产生新的、有价值的内容，在製药领域，它被证明是一个游戏规则的改变者。该市场的特点是生成式人工智慧在药物发现、分子设计和各种製药製程优化的应用。该市场的主要驱动力之一是对创新药物开发的迫切需求以及加速药物发现过程的紧迫性。生成式人工智慧透过预测潜在候选药物、优化分子结构并显着减少与传统方法相关的时间和成本，为药物发现带来前所未有的效率。製药公司越来越认识到生成式人工智慧在发现新的治疗标靶和加快先导化合物的识别方面的潜力。该技术能够分析包括生物和化学资讯在内的大量数据集，使研究人员能够做出数据驱动的决策，从而提高药物开发的整体成功率。

此外，全球製药市场生成人工智慧正在见证製药公司与人工智慧技术提供者之间的合作和伙伴关係。这些合作旨在利用两个领域的优势，将製药专业知识与先进的人工智慧功能相结合，以应对药物发现和开发中的复杂挑战。该市场的另一个特点是专门从事製药人工智慧应用的新创公司的出现，为该行业带来了创新和敏捷性。随着监管机构越来越认识到生成式人工智慧在增强药物开发流程方面的潜力，该市场可能会进一步成长。

然而，资料隐私问题、道德考量和人工智慧产生结果的可解释性等挑战是业界必须解决的问题，以促进广泛采用。随着製药公司寻求在快速发展的环境中保持竞争力，全球製药市场的生成式人工智慧有望大幅扩张。生成式人工智慧可望加速药物发现、降低开发成本并提高临床试验的成功率，正在重塑药物研发的未来。

市场概况
预测期 2024-2028
2022 年市场规模 19.6亿美元
2028 年市场规模 83.9亿美元
2023-2028 年CAGR 27.62%
成长最快的细分市场 药物发现
最大的市场 北美洲

主要市场驱动因素

目录

第 1 章：产品概述

  • 市场定义
  • 市场范围
    • 涵盖的市场
    • 考虑学习的年份
    • 主要市场区隔

第 2 章：研究方法

  • 研究目的
  • 基线方法
  • 主要产业伙伴
  • 主要协会和二手资料来源
  • 预测方法
  • 数据三角测量与验证
  • 假设和限制

第 3 章：执行摘要

  • 市场概况
  • 主要市场细分概述
  • 主要市场参与者概述
  • 重点地区/国家概况
  • 市场驱动因素、挑战、趋势概述

第 4 章：全球生成式人工智慧在製药市场的展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型（小分子、大分子）
    • 按应用（临床试验研究、药物发现、研究与开发、其他）
    • 按技术（深度学习、自然语言处理、查询方法、情境感知处理、其他）
    • 按地区
    • 按公司划分 (2022)
  • 市场地图
    • 依药物类型
    • 按应用
    • 依技术
    • 按地区

第 5 章：亚太地区生成式人工智慧在製药市场的展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型
    • 按应用
    • 依技术
    • 按国家/地区
  • 亚太地区：国家分析
    • 中国製药领域的生成式人工智慧
    • 印度製药领域的生成式人工智慧
    • 澳洲製药领域的生成式人工智慧
    • 日本製药领域的生成式人工智慧
    • 韩国製药领域的生成式人工智慧

第 6 章：欧洲生成式人工智慧在製药市场的展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型
    • 按应用
    • 依技术
    • 按国家/地区
  • 欧洲：国家分析
    • 法国
    • 德国
    • 西班牙
    • 义大利
    • 英国

第 7 章：北美生成式人工智慧在製药市场的展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型
    • 按应用
    • 依技术
    • 按国家/地区
  • 北美：国家分析
    • 美国
    • 墨西哥
    • 加拿大

第 8 章：南美洲生成式人工智慧在製药市场的展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型
    • 按应用
    • 依技术
    • 按国家/地区
  • 南美洲：国家分析
    • 巴西
    • 阿根廷
    • 哥伦比亚

第 9 章：中东和非洲製药市场中的生成式人工智慧展望

  • 市场规模及预测
    • 按价值
  • 市占率及预测
    • 依药物类型
    • 按应用
    • 依技术
    • 按国家/地区
  • MEA：国家分析
    • 南非 製药领域的生成式人工智慧
    • 沙乌地阿拉伯製药领域的生成式人工智慧
    • 阿联酋製药领域的生成式人工智慧
    • 埃及 製药领域的生成式人工智慧

第 10 章：市场动态

  • 司机
  • 挑战

第 11 章：市场趋势与发展

  • 最近的发展
  • 产品发布
  • 併购

第 12 章：製药市场的全球生成人工智慧：SWOT 分析

第 13 章：波特的五力分析

  • 产业竞争
  • 新进入者的潜力
  • 供应商的力量
  • 客户的力量
  • 替代产品的威胁

第14章：竞争格局

  • 阿斯特捷利康公司
    • Business Overview
    • Company Snapshot
    • Products & Services
    • Current Capacity Analysis
    • Financials (In case of listed)
    • Recent Developments
    • SWOT Analysis
  • 英伟达
  • 百度
  • 强生公司
  • 赛诺菲
  • 适应生物

第 15 章：策略建议

第 16 章：关于我们与免责声明

简介目录
Product Code: 20056

Global Generative AI in Pharmaceutical Market has valued at USD 1.96 billion in 2022 and is anticipated to project robust growth in the forecast period with a CAGR of 27.62% through 2028. The Global Generative AI in Pharmaceutical Market is witnessing a transformative wave as artificial intelligence (AI) continues to revolutionize the pharmaceutical industry. Generative AI, a subset of AI, utilizes advanced algorithms and models to generate new, valuable content, and in the pharmaceutical sector, it is proving to be a game-changer. This market is characterized by the application of generative AI in drug discovery, molecular design, and optimization of various pharmaceutical processes. One of the primary drivers of this market is the pressing need for innovative drug development and the urgency to accelerate the drug discovery process. Generative AI brings unprecedented efficiency to drug discovery by predicting potential drug candidates, optimizing molecular structures, and significantly reducing the time and cost associated with traditional methods. Pharmaceutical companies are increasingly recognizing the potential of generative AI in uncovering novel therapeutic targets and expediting the identification of lead compounds. The technology's ability to analyze vast datasets, including biological and chemical information, enables researchers to make data-driven decisions, enhancing the overall success rate of drug development.

Moreover, the Global Generative AI in Pharmaceutical Market is witnessing collaborations and partnerships between pharmaceutical companies and AI technology providers. These collaborations aim to leverage the strengths of both sectors, combining pharmaceutical expertise with advanced AI capabilities to address complex challenges in drug discovery and development. The market is also marked by the emergence of startups specializing in generative AI applications for pharmaceuticals, bringing innovation and agility to the industry. As regulatory bodies increasingly acknowledge the potential of generative AI in enhancing drug development processes, the market is likely to experience further growth.

However, challenges such as data privacy concerns, ethical considerations, and the interpretability of AI-generated results are issues that the industry must address to foster widespread adoption. The Global Generative AI in Pharmaceutical Market is poised for significant expansion as pharmaceutical companies seek to stay competitive in a rapidly evolving landscape. With the promise of faster drug discovery, reduced development costs, and improved success rates in clinical trials, generative AI is reshaping the future of pharmaceutical research and development.

Market Overview
Forecast Period2024-2028
Market Size 2022USD 1.96 Billion
Market Size 2028USD 8.39 Billion
CAGR 2023-202827.62%
Fastest Growing SegmentDrug Discovery
Largest MarketNorth America

Key Market Drivers

Accelerated Drug Discovery and Development

Accelerated drug discovery and development have emerged as a catalyst for the remarkable growth of the Global Generative AI in Pharmaceutical Market. Traditional methods of drug discovery are often protracted and resource-intensive, with a considerable number of potential drug candidates failing to progress through the various stages of development. Generative AI addresses this bottleneck by harnessing the power of advanced algorithms to swiftly analyze vast datasets. This acceleration is particularly evident in the early stages of drug discovery, where generative AI models predict potential drug candidates and optimize molecular structures with remarkable speed and precision. By efficiently navigating the expansive landscape of biological and chemical data, generative AI enables pharmaceutical researchers to identify promising compounds in a fraction of the time it would take using conventional approaches. This acceleration not only expedites the overall drug discovery process but also significantly reduces the associated costs, making the adoption of generative AI an attractive proposition for pharmaceutical companies striving for efficiency and competitiveness in the fast-paced industry.

Generative AI's contribution to accelerating drug development extends beyond the initial stages, encompassing optimization and refinement throughout the entire drug development lifecycle. The technology aids in the design of clinical trials, helping researchers identify optimal patient populations, refine inclusion criteria, and enhance the likelihood of successful trial outcomes. By leveraging generative AI insights, pharmaceutical companies can make data-driven decisions at every phase, reducing the time and resources required for clinical development. This acceleration is crucial, especially in addressing urgent medical needs and responding rapidly to emerging health challenges, where timely access to effective therapies is paramount.

Moreover, the speed and efficiency introduced by generative AI in drug development align with the industry's quest for personalized medicine. Tailoring treatments to individual patient profiles requires a nuanced understanding of complex biological interactions, and generative AI excels in deciphering these intricate relationships within vast datasets. This capability not only accelerates the identification of personalized treatment options but also contributes to the evolution of precision medicine, where therapies are finely tuned to match the unique characteristics of each patient.

Optimization of Drug Formulation and Manufacturing Processes

The Global Generative AI in Pharmaceutical Market is experiencing a significant boost due to its pivotal role in the optimization of drug formulation and manufacturing processes. Traditionally, drug formulation and manufacturing have been intricate processes requiring careful experimentation and iterative refinement. Generative AI is changing this landscape by employing advanced algorithms to analyze complex interactions within pharmaceutical formulations. This technology allows for the prediction and optimization of drug formulations with unprecedented speed and accuracy. By exploring a multitude of variables and parameters, generative AI models can propose formulations that enhance drug stability, solubility, and bioavailability. This not only expedites the formulation process but also contributes to the development of more efficacious and patient-friendly drug products.

In manufacturing processes, generative AI is instrumental in optimizing production conditions, ensuring consistency, and minimizing variations. The technology's ability to analyze large datasets, including information on raw materials, manufacturing equipment, and process parameters, enables it to identify optimal manufacturing settings. This optimization leads to improved efficiency in the production of pharmaceuticals, reducing costs and enhancing overall manufacturing quality. Generative AI also plays a crucial role in addressing challenges related to scale-up, ensuring that successful formulations at the laboratory scale can be seamlessly translated to larger production scales.

Furthermore, generative AI facilitates the exploration of innovative drug delivery mechanisms, including nanotechnology and personalized drug delivery systems. By generating insights into the most effective delivery methods based on patient characteristics and the nature of the therapeutic agent, generative AI contributes to the development of tailored drug delivery solutions. This personalized approach not only improves patient adherence and outcomes but also aligns with the growing trend toward precision medicine in the pharmaceutical industry.

The optimization of drug formulation and manufacturing processes driven by generative AI aligns with the pharmaceutical industry's continuous pursuit of efficiency, cost-effectiveness, and quality in drug development. As the demand for novel and improved pharmaceutical products intensifies, generative AI provides a powerful tool to streamline and enhance formulation and manufacturing practices. The resulting benefits include accelerated time-to-market for new drugs, reduced production costs, and the ability to respond swiftly to changing market demands. With these advantages, generative AI is emerging as a transformative force in pharmaceutical formulation and manufacturing, offering a pathway to innovation and optimization in an industry that demands precision and efficiency.

Drug Repurposing and Combination Therapies

Drug repurposing and the exploration of combination therapies have become key drivers in propelling the Global Generative AI in Pharmaceutical Market. Generative AI is playing a crucial role in identifying new applications for existing drugs, known as drug repurposing, by leveraging its ability to analyze vast datasets and predict potential therapeutic uses. This approach offers a cost-effective and time-efficient alternative to traditional drug development, as it taps into the wealth of information on approved drugs, their targets, and associated biological pathways. Generative AI models can uncover novel indications for existing drugs, facilitating the rapid identification of repurposable candidates and shortening the time required for clinical validation.

Moreover, the market is witnessing a surge in the exploration of combination therapies, where multiple drugs are strategically combined to enhance efficacy or reduce side effects. Generative AI contributes by predicting synergistic drug combinations based on complex interactions within biological systems. The technology can analyze extensive datasets related to drug interactions, molecular pathways, and patient-specific data, offering insights into combinations that may exhibit enhanced therapeutic effects. This approach aligns with the shift toward personalized medicine, as generative AI can tailor combination therapies to individual patient profiles, optimizing treatment outcomes.

The advantages of drug repurposing and combination therapies are multifaceted, and generative AI is at the forefront of unlocking their full potential. By identifying new therapeutic uses for existing drugs, drug repurposing mitigates the risks associated with developing entirely new compounds, often expediting the time it takes for a drug to reach the market. Combination therapies, on the other hand, address the complexities of diseases that may not be fully addressed by single-agent treatments, providing a more comprehensive approach to patient care. The application of generative AI in these areas enhances the efficiency and success rates of drug repurposing and combination therapy strategies, making them more appealing to pharmaceutical companies seeking innovative and effective treatment solutions.

Key Market Challenges

Issue Of Data Privacy and Security

The Global Generative AI in Pharmaceutical Market is encountering a significant impediment in the form of data privacy and security concerns. As pharmaceutical companies increasingly leverage generative AI technologies to expedite drug discovery and development processes, the sensitive nature of the data involved becomes a critical challenge. The industry deals with a vast array of confidential information, including patient data, proprietary molecular structures, and clinical trial results. The potential misuse or unauthorized access to this data poses a substantial threat, hindering the seamless integration of generative AI in pharmaceutical research.

One of the primary concerns in the context of data privacy is the risk of inadvertent data breaches. The vast datasets used by generative AI models may include personal and health-related information, making them attractive targets for cyberattacks. The unauthorized access to such information not only jeopardizes patient privacy but also exposes pharmaceutical companies to legal and regulatory consequences. As a result, there is a growing need for robust cybersecurity measures to safeguard the integrity and confidentiality of sensitive data used in generative AI applications.

Moreover, compliance with data protection regulations, such as the General Data Protection Regulation (GDPR) in Europe and the Health Insurance Portability and Accountability Act (HIPAA) in the United States, adds another layer of complexity. Generative AI applications in pharmaceuticals must navigate these stringent regulatory frameworks to ensure that the collection, processing, and storage of sensitive data adhere to established guidelines. Achieving and maintaining compliance with these regulations requires a comprehensive understanding of both AI technologies and the intricacies of data protection laws.

Interpretability Of AI-Generated Results

Generative AI, particularly deep learning models, is often characterized by its black-box nature, meaning that the inner workings of the algorithms are complex and not easily understandable by human operators. In the pharmaceutical sector, where decisions can have profound implications on patient health, regulatory compliance, and business outcomes, the black-box nature of AI poses a significant challenge. Stakeholders, including researchers, clinicians, and regulatory bodies, may struggle to trust and interpret the results generated by these algorithms.

The pharmaceutical industry is highly regulated, and ensuring compliance with regulatory standards is paramount. However, the lack of interpretability in AI-generated results raises concerns about meeting regulatory requirements. Regulatory bodies need to understand how AI models arrive at conclusions to ensure that decisions align with ethical guidelines and safety standards. The inability to interpret AI-generated results complicates the process of gaining regulatory approval for new drugs and treatments, hindering the widespread adoption of Generative AI in pharmaceutical research and development.

Trust is a cornerstone of any successful technology integration, and the interpretability challenge directly impacts the trust that stakeholders place in AI-generated results. Researchers, clinicians, and decision-makers may be hesitant to rely on AI-driven insights if they cannot understand how the system arrives at its conclusions. This limited trust can impede the adoption of Generative AI in critical areas such as drug discovery, where transparency and accountability are essential for success.

Key Market Trends

Increasing Focus on Personalized Medicine

The global pharmaceutical market is undergoing a revolutionary shift fueled by the increasing focus on personalized medicine, a trend that is significantly boosting the adoption of Generative Artificial Intelligence (Generative AI). As the pharmaceutical industry recognizes the limitations of one-size-fits-all treatments, there is a growing emphasis on tailoring therapies to individual patients based on their unique genetic makeup, health history, and specific characteristics.

Generative AI emerges as a key enabler in this paradigm shift, offering advanced algorithms capable of analyzing vast and diverse datasets to generate personalized treatment options. By leveraging Generative AI, pharmaceutical researchers can identify optimal drug candidates that align with the specific genetic and biological markers of individual patients. This trend not only enhances treatment efficacy but also minimizes potential side effects, resulting in more targeted and efficient therapeutic interventions.

The intersection of Generative AI and personalized medicine is paving the way for a new era in healthcare, where treatments are precisely tailored to meet the individual needs of patients, ushering in unprecedented levels of effectiveness and patient care. As the focus on personalized medicine intensifies, the global Generative AI in the pharmaceutical market is poised for sustained growth, offering transformative solutions to the challenges of traditional drug development and positioning itself as a cornerstone of the future of healthcare.

Integration of Generative AI in Drug Repurposing

The integration of Generative Artificial Intelligence (Generative AI) in drug repurposing is a dynamic trend that is significantly propelling the global Generative AI in the pharmaceutical market. Drug repurposing, or repositioning existing drugs for new therapeutic applications, has gained prominence as a strategy to accelerate the development of treatments for various diseases.

Generative AI plays a pivotal role in this process by leveraging its capacity to analyze extensive datasets, including clinical trial results, molecular structures, and biological pathways. By harnessing sophisticated algorithms, Generative AI identifies potential drug candidates for repurposing, offering a more efficient and cost-effective alternative to traditional drug discovery methods. This trend is particularly crucial in addressing urgent medical needs and optimizing the utilization of existing pharmaceutical resources.

The ability of Generative AI to rapidly sift through vast amounts of data, predict potential drug interactions, and propose novel therapeutic applications is reshaping the landscape of drug development. This integration not only expedites the identification of viable candidates but also contributes to the overall sustainability of pharmaceutical research and development. As the pharmaceutical industry recognizes the value of repurposing existing drugs to address emerging health challenges, the integration of Generative AI in drug repurposing is fostering a climate of innovation, efficiency, and resource optimization. This trend is poised to play a pivotal role in shaping the future of pharmaceutical research, offering novel solutions to complex medical problems and contributing to the continued growth of the global Generative AI market in the pharmaceutical sector.

Segmental Insights

Drug Type Insights

Based on the Drug Type, small molecules emerged as the dominant segment in the global market for Global Generative AI in Pharmaceutical in 2022. Small molecules are organic compounds with low molecular weight that can easily penetrate cell membranes, allowing them to interact with specific targets within cells. These small molecules have historically dominated the pharmaceutical landscape due to their oral bioavailability, ease of manufacturing, and broad range of targetable diseases. Generative AI plays a crucial role in the discovery of small molecule drugs. The technology can analyze vast datasets containing information on chemical structures, biological activity, and pharmacological properties to predict novel small molecule compounds with therapeutic potential. By generating molecular structures that align with desired biological activities, generative AI expedites the identification of promising drug candidates. This efficiency is particularly valuable in the early stages of drug discovery, where the goal is to find compounds with the right balance of efficacy, safety, and pharmacokinetic properties.

Application Insights

Based on the Application, Drug Discovery emerged as the dominant segment in the global market for Global Generative AI in Pharmaceutical Market in 2022. Generative AI's ability to predict molecular structures and properties, propose novel combinations, and optimize lead compounds aligns well with the iterative and exploratory nature of drug discovery. Pharmaceutical companies are increasingly turning to generative AI to enhance their early-stage research and identify promising candidates for further experimental validation. While Drug Discovery is a critical application, it's important to note that other applications, such as Clinical Trial Research and Research and Development, also play significant roles in the pharmaceutical industry. Clinical Trial Research leverages generative AI to optimize trial design, patient recruitment, and data analysis, ultimately improving the efficiency of clinical trials. Research and Development broadly encompasses various stages of drug development, and generative AI contributes to optimizing processes and decision-making across these stages..

Regional Insights

North America emerged as the dominant player in the Global Generative AI in Pharmaceutical Market in 2022, holding the largest market share. North America, particularly the United States, possesses a highly advanced technological infrastructure. The region is home to numerous pharmaceutical and biotechnology companies that are early adopters of cutting-edge technologies, including Generative AI. The presence of well-established research and development facilities contributes to North America's leadership in incorporating innovative solutions like Generative AI in pharmaceutical processes. North American pharmaceutical companies often engage in strategic collaborations and partnerships with technology providers, including those specializing in Generative AI. These collaborations facilitate the exchange of expertise, resources, and technologies, fostering innovation and the integration of advanced AI solutions in drug discovery, development, and manufacturing.

Key Market Players

AstraZeneca Plc

Nvidia

Baidu

Johnson & Johnson

Sanofi

Adaptyv Bio

Report Scope:

In this report, the Global Generative AI in Pharmaceutical Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Global Generative AI in Pharmaceutical Market, By Drug Type:

  • Small Molecule
  • Large Molecule

Global Generative AI in Pharmaceutical Market, By Application:

  • Clinical Trial Research
  • Drug Discovery
  • Research And Development
  • Others

Global Generative AI in Pharmaceutical Market, By Technology:

  • Deep Learning
  • Natural Language Processing
  • Querying Method
  • Context-aware Processing
  • Others

Global Generative AI in Pharmaceutical Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait
  • Turkey
  • Egypt

Competitive Landscape

  • Company Profiles: Detailed analysis of the major companies present in the Global Generative AI in Pharmaceutical Market.

Available Customizations:

  • Global Generative AI in Pharmaceutical Market report with the given market data, Tech Sci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Global Generative AI in Pharmaceutical Market Outlook

  • 4.1. Market Size & Forecast
    • 4.1.1. By Value
  • 4.2. Market Share & Forecast
    • 4.2.1. By Drug Type (Small Molecule, Large Molecule)
    • 4.2.2. By Application (Clinical Trial Research, Drug Discovery, Research And Development, Others)
    • 4.2.3. By Technology (Deep Learning, Natural Language Processing, Querying Method, Context-aware Processing, Others)
    • 4.2.4. By Region
    • 4.2.5. By Company (2022)
  • 4.3. Market Map
    • 4.3.1. By Drug Type
    • 4.3.2. By Application
    • 4.3.3. By Technology
    • 4.3.4. By Region

5. Asia Pacific Generative AI in Pharmaceutical Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Drug Type
    • 5.2.2. By Application
    • 5.2.3. By Technology
    • 5.2.4. By Country
  • 5.3. Asia Pacific: Country Analysis
    • 5.3.1. China Generative AI in Pharmaceutical Market Outlook
      • 5.3.1.1. Market Size & Forecast
        • 5.3.1.1.1. By Value
      • 5.3.1.2. Market Share & Forecast
        • 5.3.1.2.1. By Drug Type
        • 5.3.1.2.2. By Application
        • 5.3.1.2.3. By Technology
    • 5.3.2. India Generative AI in Pharmaceutical Market Outlook
      • 5.3.2.1. Market Size & Forecast
        • 5.3.2.1.1. By Value
      • 5.3.2.2. Market Share & Forecast
        • 5.3.2.2.1. By Drug Type
        • 5.3.2.2.2. By Application
        • 5.3.2.2.3. By Technology
    • 5.3.3. Australia Generative AI in Pharmaceutical Market Outlook
      • 5.3.3.1. Market Size & Forecast
        • 5.3.3.1.1. By Value
      • 5.3.3.2. Market Share & Forecast
        • 5.3.3.2.1. By Drug Type
        • 5.3.3.2.2. By Application
        • 5.3.3.2.3. By Technology
    • 5.3.4. Japan Generative AI in Pharmaceutical Market Outlook
      • 5.3.4.1. Market Size & Forecast
        • 5.3.4.1.1. By Value
      • 5.3.4.2. Market Share & Forecast
        • 5.3.4.2.1. By Drug Type
        • 5.3.4.2.2. By Application
        • 5.3.4.2.3. By Technology
    • 5.3.5. South Korea Generative AI in Pharmaceutical Market Outlook
      • 5.3.5.1. Market Size & Forecast
        • 5.3.5.1.1. By Value
      • 5.3.5.2. Market Share & Forecast
        • 5.3.5.2.1. By Drug Type
        • 5.3.5.2.2. By Application
        • 5.3.5.2.3. By Technology

6. Europe Generative AI in Pharmaceutical Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Drug Type
    • 6.2.2. By Application
    • 6.2.3. By Technology
    • 6.2.4. By Country
  • 6.3. Europe: Country Analysis
    • 6.3.1. France Generative AI in Pharmaceutical Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Drug Type
        • 6.3.1.2.2. By Application
        • 6.3.1.2.3. By Technology
    • 6.3.2. Germany Generative AI in Pharmaceutical Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Drug Type
        • 6.3.2.2.2. By Application
        • 6.3.2.2.3. By Technology
    • 6.3.3. Spain Generative AI in Pharmaceutical Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Drug Type
        • 6.3.3.2.2. By Application
        • 6.3.3.2.3. By Technology
    • 6.3.4. Italy Generative AI in Pharmaceutical Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Drug Type
        • 6.3.4.2.2. By Application
        • 6.3.4.2.3. By Technology
    • 6.3.5. United Kingdom Generative AI in Pharmaceutical Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Drug Type
        • 6.3.5.2.2. By Application
        • 6.3.5.2.3. By Technology

7. North America Generative AI in Pharmaceutical Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Drug Type
    • 7.2.2. By Application
    • 7.2.3. By Technology
    • 7.2.4. By Country
  • 7.3. North America: Country Analysis
    • 7.3.1. United States Generative AI in Pharmaceutical Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Drug Type
        • 7.3.1.2.2. By Application
        • 7.3.1.2.3. By Technology
    • 7.3.2. Mexico Generative AI in Pharmaceutical Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Drug Type
        • 7.3.2.2.2. By Application
        • 7.3.2.2.3. By Technology
    • 7.3.3. Canada Generative AI in Pharmaceutical Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Drug Type
        • 7.3.3.2.2. By Application
        • 7.3.3.2.3. By Technology

8. South America Generative AI in Pharmaceutical Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Drug Type
    • 8.2.2. By Application
    • 8.2.3. By Technology
    • 8.2.4. By Country
  • 8.3. South America: Country Analysis
    • 8.3.1. Brazil Generative AI in Pharmaceutical Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Drug Type
        • 8.3.1.2.2. By Application
        • 8.3.1.2.3. By Technology
    • 8.3.2. Argentina Generative AI in Pharmaceutical Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Drug Type
        • 8.3.2.2.2. By Application
        • 8.3.2.2.3. By Technology
    • 8.3.3. Colombia Generative AI in Pharmaceutical Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Drug Type
        • 8.3.3.2.2. By Application
        • 8.3.3.2.3. By Technology

9. Middle East and Africa Generative AI in Pharmaceutical Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Drug Type
    • 9.2.2. By Application
    • 9.2.3. By Technology
    • 9.2.4. By Country
  • 9.3. MEA: Country Analysis
    • 9.3.1. South Africa Generative AI in Pharmaceutical Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Drug Type
        • 9.3.1.2.2. By Application
        • 9.3.1.2.3. By Technology
    • 9.3.2. Saudi Arabia Generative AI in Pharmaceutical Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Drug Type
        • 9.3.2.2.2. By Application
        • 9.3.2.2.3. By Technology
    • 9.3.3. UAE Generative AI in Pharmaceutical Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Drug Type
        • 9.3.3.2.2. By Application
        • 9.3.3.2.3. By Technology
    • 9.3.4. Egypt Generative AI in Pharmaceutical Market Outlook
      • 9.3.4.1. Market Size & Forecast
        • 9.3.4.1.1. By Value
      • 9.3.4.2. Market Share & Forecast
        • 9.3.4.2.1. By Drug Type
        • 9.3.4.2.2. By Application
        • 9.3.4.2.3. By Technology

10. Market Dynamics

  • 10.1. Drivers
  • 10.2. Challenges

11. Market Trends & Developments

  • 11.1. Recent Developments
  • 11.2. Product Launches
  • 11.3. Mergers & Acquisitions

12. Global Generative AI in Pharmaceutical Market: SWOT Analysis

13. Porter's Five Forces Analysis

  • 13.1. Competition in the Industry
  • 13.2. Potential of New Entrants
  • 13.3. Power of Suppliers
  • 13.4. Power of Customers
  • 13.5. Threat of Substitute Product
  • 13.6.

14. Competitive Landscape

  • 14.1. AstraZeneca Plc
    • 14.1.1. Business Overview
    • 14.1.2. Company Snapshot
    • 14.1.3. Products & Services
    • 14.1.4. Current Capacity Analysis
    • 14.1.5. Financials (In case of listed)
    • 14.1.6. Recent Developments
    • 14.1.7. SWOT Analysis
  • 14.2. Nvidia
  • 14.3. Baidu
  • 14.4. Johnson & Johnson
  • 14.5. Sanofi
  • 14.6. Adaptyv Bio

15. Strategic Recommendations

16. About Us & Disclaimer